Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr-Jun;69(2):158-163.
doi: 10.22336/rjo.2025.26.

Transepithelial photorefractive keratectomy - an analysis of the solutions offered by the industry nowadays

Affiliations
Review

Transepithelial photorefractive keratectomy - an analysis of the solutions offered by the industry nowadays

Daiana-Andreea Margarit et al. Rom J Ophthalmol. 2025 Apr-Jun.

Abstract

Purpose: To review and compare the current commercial solutions for transepithelial photorefractive keratectomy (TransPRK) offered by leading excimer laser manufacturers-SCHWIND eye-tech-solutions (AMARIS with SmartPulse), Alcon (WaveLight EX500), and Bausch + Lomb Technolas (TENEO 317), with a focus on technology, treatment protocols, and clinical outcomes.

Background: TransPRK, a no-touch surface ablation technique, eliminates mechanical or alcohol-based epithelial removal by using the excimer laser to ablate both epithelium and stromal tissue in a single step. This approach offers advantages, including lower epithelial trauma, reduced risk of infection, and faster epithelial healing. Industry innovation has significantly improved TransPRK outcomes through refined epithelial mapping, high-speed ablation, and advanced eye-tracking systems.All three platforms-SCHWIND AMARIS, WaveLight EX500, and Technolas TENEO-offer effective TransPRK capabilities, each with distinctive advantages. SCHWIND currently leads in terms of surface quality and early visual recovery due to SmartPulse Technology. WaveLight EX500 provides high-speed ablation and robust platform integration, while Technolas TENEO offers customizable epithelial profiles and a user-friendly interface.

Conclusion: In summary, modern TransPRK systems provide safe, effective, and increasingly customizable options for correcting myopia and astigmatism. The choice between platforms depends on a range of factors, including surgical goals, patient profile, available technology, and the surgeon's familiarity with the system. As laser platforms continue to evolve, further innovations in epithelial mapping, real-time ablation control, and surface smoothing may continue to enhance the outcomes and expand the indications for TransPRK.

Keywords: CDVA = Corrected distance visual acuity; Excimer laser; LASIK = Laser-Assisted in Situ Keratomileusis; PRK = Photorefractive Keratectomy; PTK = Phototherapeutic Keratectomy; SPT = SmartPulse Technology; SmartPulse; Streamlight; TransEpi PRK; TransPRK; TransPRK = Transepithelial Photorefractive Keratectomy; UDVA = Uncorrected distance visual acuity.

PubMed Disclaimer

Conflict of interest statement

The authors state no conflict of interest.

Similar articles

References

    1. Way C, Elghobaier MG, Nanavaty MA. Transepithelial photorefractive keratectomy—a narrative review. Eye Vis (Lond) 2023;10(1):16. doi: 10.1186/s40662-023-00316-0. - DOI
    1. Luger MHA, Ewering T, Arba-Mosquera S, Kretz FTA. Clinical outcomes after SmartSurface TransPRK using the SCHWIND Amaris system. Clinical Ophthalmology (Auckland N.Z.) 2021;15:2039–2047. doi: 10.2147/OPTH.S308311. - DOI
    1. Xi L, Zhang C, He Y. Clinical outcomes of transepithelial photorefractive keratectomy to treat low to moderate myopic astigmatism. BMC Ophthalmol. 2018;18:115. doi: 10.1186/s12886-018-0775-5. - DOI - PMC - PubMed
    1. Bausch + Lomb Technolas TENEO 317 Model: Manufacturer’s documentation and user experiences https://www.bauschsurgical.com .
    1. Alasbali T. Transepithelial Photorefractive Keratectomy Compared to Conventional Photorefractive Keratectomy: A Meta-Analysis. J Ophthalmol. 2022 Aug 23;2022:3022672. doi: 10.1155/2022/3022672. PMCID: PMC9427238. - DOI - PMC - PubMed

LinkOut - more resources